Growth inhibitory effects of 1α, 25-Dihydroxyvitamin D3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7122-7129

  Moffatt, K A ^a   Johannes, W U ^a   Hedlund, T E ^a   Miller, G J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COMPLEMENTARY DNA; LUCIFERASE; MESSENGER RNA; PROTEIN; PROTEIN P21; VITAMIN D RECEPTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MODEL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

CALCITRIOL; CELL COUNT; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035477461     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Cancer statistics, 2000
2. Early prostate cancer diagnosis and therapy
3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
4. Vitamin D and bone health
5. Mechanisms and functions of vitamin D
6. The role of vitamin D in immunosuppression: Lessons from autoimmunity and transplantation
7. Vitamin D in the nervous system: Actions and therapeutic potential
8. Differentiation of mouse myeloid leukemia cells induced by 1 α,25-dihydroxyvitamin D3
9. Superfamily of steroid nuclear receptors: Positive and negative regulators of gene expression
10. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed
11. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells
12. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines
13. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089
14. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases
15. In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma
16. Vitamin D and prostate cancer: A prediagnostic study with stored sera
17. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men
18. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
19. Association of prostate cancer with vitamin D receptor gene polymorphism
20. Vitamin D. Deficiency and elevation of parathyroid hormone levels in patients with advanced hormone refractory prostate cancer
21. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy
22. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells
23. 1 accumulation
24. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1α,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells
25. Effects of vitamin D3 on proliferation of cancer cells in vitro
26. 1α,25-Dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent
27. Specific receptors for vitamin D3 in human prostatic carcinoma cells
28. Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31
29. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: Evidence that the antiproliferative effects of 1 α, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway
30. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
31. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
32. Transcriptional regulation of the p21((WAF1/CIP1)) gene
33. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells
34. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
35. LNCaP model of human prostatic carcinoma
36. Human primary prostate tumor cell line, ALVA-31: A new model for studying the hormonal regulation of prostate tumor cell growth
37. Isolation of a human prostate carcinoma cell line (DU 145)
38. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
39. Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma
40. Establishment of a new prostatic carcinoma cell line (TSU-Pr1)
41. Establishment of new human prostatic cancer cell line (JCA-1)
42. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice
43. A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines
44. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
45. Improved retroviral vectors for gene transfer and expression
46. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells
47. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
48. Collaborative role of E2F transcriptional activity and G1 cyclin dependent kinase activity in the induction of S phase
49. 1α,25Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines
50. p21-containing cyclin kinases exist in both active and inactive states
51. Newly identified actions of the vitamin D endocrine system
52. Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction
53. Inhibitors of mammalian G1 cyclin-dependent kinases
54. Calcitonin receptor-mediated growth suppression of HEK-293 cells is accompanied by induction of p21WAF1/CIP1 and G2/M arrest
55. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1
56. Karyotypic similarity identified by multiplex-FISH relates four prostate adenocarcinoma cell lines: PC-3, PPC-1, ALVA-31, and ALVA-41
57. Widely used prostate carcinoma cell lines share common origins
58. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin
59. WAF1, a potential mediator of p53 tumor suppression
60. p21/p53, cellular growth control and genomic integrity
61. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers
62. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
63. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer
64. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas